Clinical Trials · NCT05003752
Hypo-Combi Trial: Hypofractionated EBRT Plus HDR-BT Boost for Prostate Cancer
- Phase
- Phase 1/Phase 2
- Recruitment status
- Active Not Recruiting
- Sponsor
- German Oncology Center, Cyprus
- Enrollment
- 40
- Start date
- Aug 2021
- Locations
- 1 site, Cyprus
- Primary endpoint
- Rate of acute and early late genitourinary, gastrointestinal and sexual toxicity